Breakthrough in Aging Research as Human Trials Begin
A groundbreaking injection aimed at reversing aging has been administered to a human for the first time.
This marks a significant milestone in the field of longevity science, allowing researchers to investigate if epigenetic reprogramming—a method intended to rejuvenate aging cells—can actually enhance how people age in real life.
On Tuesday, a biotech company named Life Biosciences, based in Boston, announced that its initial patient had received a reprogramming injection that targets age-related diseases.
High-profile investors, like Jeff Bezos and Sam Altman, alongside major pharmaceutical companies such as Eli Lilly and Merck, have shown increasing interest in this concept, which had previously been limited to research on mice and monkeys.
If this initial human trial proves successful, it could lead to a new wave of therapies focused on rejuvenating cells throughout the body, ultimately aiming to improve the expression of our DNA as we grow older.
The injection was administered in one eye of a single individual diagnosed with glaucoma. Specific details about the patient were not disclosed. Over the next six months, researchers will closely monitor the technique’s effectiveness and watch for any safety concerns.
“This could be a transformative moment—not just for our company, but for the field of aging biology, and I think for medicine as a whole,” said Life Biosciences CEO Jerry McLaughlin in an interview.
“We are truly exploring the potential to restore function and reverse disease in the body at its fundamental level,” he added.
Understanding Cellular Reprogramming
The idea of cellular reprogramming has excited researchers in longevity science for nearly twenty years. In 2007, scientist Shinya Yamanaka achieved the first successful reprogramming of adult human cells, a discovery that later earned him a Nobel Prize. The four proteins he identified, known as the “Yamanaka Factors,” can essentially reset cells to a younger, more agile state.
Researchers in longevity science are eager to find methods to partially reprogram older cells, enabling them to become more youthful without reverting entirely to their undifferentiated stem cell states. Areas like liver and muscle cells are currently heavily researched, aiming to enhance the performance of cells in these areas as we age.
In recent years, significant funding has been directed towards unlocking safe and effective ways to test partial reprogramming techniques in living humans without causing complete cellular reversion.
Major pharmaceutical companies are taking notice. Eli Lilly recently participated in a large $435 million funding round for another biotech startup, New Limit, which also focuses on cellular reprogramming. Meanwhile, Merck Animal Health has invested in Rejuvenate Bio, and tech leaders like Jeff Bezos and Sam Altman continue to finance Silicon Valley startups based on this promising idea.
However, Life Biosciences stands out as the first to initiate human trials, with plans for approximately 20 patients to be part of the FDA trial of ER-100. Clinics located in Boston, New York City, Los Angeles, and Charleston are looking to recruit patients suffering from glaucoma or a common form of vision loss called NAION.
One of the company’s co-founders, David Sinclair, is a prominent yet controversial figure in longevity studies. Although he no longer has day-to-day involvement at Life Biosciences, his ideas laid groundwork for this current trial, which could be groundbreaking if successful.
Assessing Risks and Rewards of Cellular Reprogramming
The potential for cellular reprogramming to revolutionize our approach to diagnosis and treatment is enormous.
If cells can be engineered to function more effectively as we age, the implications extend far beyond improved eyesight and stronger muscles. Such therapies might eventually prolong healthy life—though any drugs in this area are likely still several years away from receiving FDA approval.
“We’re just at the beginning of demonstrating that this tech works; starting with the eye makes sense, but the real excitement lies in its potential for systemic changes,” noted Daniel Oliver, CEO of Rejuvenate Bio, in a recent conversation.
“These technologies become particularly thrilling when applied to muscle, liver, or neuronal tissues, as improvements in these areas tend to resonate positively throughout the body.”
Nonetheless, there are genuine concerns regarding cellular reprogramming, particularly its association with cancer. Critics remain wary, especially since two of the four identified Yamanaka factors are oncogenes, known for their ability to proliferate indefinitely. Some animal trials have seen subjects develop cancerous tumors.
In Life Biosciences’ case, researchers are employing a therapeutic control mechanism. Participants will take doxycycline, a standard antibiotic, daily to toggle the therapy on and off. If any safety issues arise during the trial, patients can discontinue the drug, effectively halting the reprogramming process. Importantly, this trial only utilizes three of the four Yamanaka factors, omitting the one most strongly linked to cancer development.
Longevity scientists recognize the potential for these therapies to significantly alter our aging process, possibly outpacing the benefits of supplements or generic medications.
Yet, they proceed with caution. On a recent podcast, longevity researcher Matt Kaeberlein queried Brian Kennedy from the Centre for Healthy Longevity about the future of this field. Kennedy expressed support for epigenetic reprogramming, noting its potential impact on aging, but admitted skepticism about the current understanding needed to ensure safety and efficacy in humans.
“That being said, exploring this avenue is intriguing, especially as the eye is somewhat isolated from the rest of the body and might have fewer side effects,” he concluded.
